Welcome to our dedicated page for Envoy Medical news (Ticker: COCH), a resource for investors and traders seeking the latest updates and insights on Envoy Medical stock.
Envoy Medical, Inc. develops hearing-health technologies focused on fully implanted hearing solutions. The company’s portfolio includes the Esteem FI-AMEI, an FDA-approved fully implanted active middle ear implant for adults with moderate to severe sensorineural hearing loss, and the investigational Acclaim cochlear implant, which uses a sensor designed to work with the ear’s natural anatomy rather than an external microphone.
Recurring company news covers Acclaim clinical-study updates, FDA-related development toward a Premarket Approval pathway, financial results, capital-structure actions, Nasdaq listing compliance, board and governance changes, and intellectual-property updates tied to its hearing segment.
Envoy Medical (Nasdaq: COCH) reported its Q1 2024 results, highlighting progress in its fully implanted cochlear implant development. All three participants in the Early Feasibility Study (EFS) at Mayo Clinic completed their 12-month follow-ups and continue using their devices daily. The company plans to file an Investigational Device Exemption (IDE) application for a pivotal clinical trial later in 2024 but has converted the current IDE application to a pre-submission for additional data collection and discussions with the FDA.
Financially, Envoy Medical reported revenue of $59K, down from $78K in Q1 2023. R&D expenses increased by $0.4M due to higher personnel costs. Sales and marketing expenses decreased by $46K, while general and administrative expenses rose by $0.7M. The company secured a $10M lending facility from investor Glen Taylor, with $5M drawn initially. Cash and cash equivalents stood at $4.9M as of March 31, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.